Advertisement
Research Article Free access | 10.1172/JCI113762
Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Find articles by Fey, M. in: JCI | PubMed | Google Scholar
Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Find articles by Wells, R. in: JCI | PubMed | Google Scholar
Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Find articles by Wainscoat, J. in: JCI | PubMed | Google Scholar
Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Find articles by Thein, S. in: JCI | PubMed | Google Scholar
Published November 1, 1988 - More info
DNA fingerprinting with three different probes (33.15, 33.6, and alpha-globin 3'HVR) was investigated as a method for the determination of clonality in gastrointestinal tumors. In 29/44 carcinomas the tumor DNA showed clonal somatic mutations that were not seen in the corresponding peripheral blood and normal mucosa samples. The changes consisted of either novel fingerprint bands, losses of bands, or both. The probe 33.15 yielded the highest rate of abnormal DNA fingerprints (21/44 carcinomas). Sequential use of the probes increased the number of cases where clonal fingerprint markers could be detected. One out of five colorectal adenomas also showed a clonal loss of a fingerprint band. In two cases of gastric cancer, DNA from the metastatic tumor had a different DNA fingerprint from that found in the primary carcinoma. DNA fingerprinting offers a novel approach to determining clonality in tumors and may prove useful for the study of tumor progression.
Images.